NASDAQ:IPSC Century Therapeutics Q2 2025 Earnings Report $2.12 -0.01 (-0.47%) Closing price 06/8/2026 04:00 PM EasternExtended Trading$2.15 +0.03 (+1.60%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Century Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.38Beat/MissMet ExpectationsOne Year Ago EPSN/ACentury Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.03 millionBeat/MissN/AYoY Revenue GrowthN/ACentury Therapeutics Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 14, 2025Conference Call Time4:00PM ETUpcoming EarningsCentury Therapeutics' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Century Therapeutics Earnings HeadlinesNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026June 8 at 4:05 PM | globenewswire.comAinos (NASDAQ:AIMD) versus Century Therapeutics (NASDAQ:IPSC) Head-To-Head SurveyJune 5, 2026 | americanbankingnews.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 9 at 1:00 AM | Weiss Ratings (Ad)Mizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendationMay 28, 2026 | msn.comCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsMay 14, 2026 | globenewswire.comCentury Therapeutics Reports First Quarter Financial Results and Business UpdatesMay 13, 2026 | globenewswire.comSee More Century Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email. Email Address About Century TherapeuticsCentury Therapeutics (NASDAQ:IPSC) is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays. The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation. Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.View Century Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Campbell's Soup Stock: Deep Value and a 7% Dividend YieldThese 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?Samsara Just Answered The AI Question—Is Wall Street Ready To Listen?Planet Labs: Coming Back Down to EarthDocusign: Another Beat, Another Selloff—Why the Analysts Are WrongA Lulu of a Miss Sends Lululemon to New Lows—Look Out BelowWhat's Make of Macy's: Berkshire Hathaway's Latest Buy Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
